Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

559 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Stereotactic radiation therapy in the strategy of treatment of metastatic renal cell carcinoma: A study of the Getug group.
Meyer E, Pasquier D, Bernadou G, Calais G, Maroun P, Bossi A, Theodore C, Albiges L, Stefan D, de Crevoisier R, Hennequin C, Lagrange JL, Grellard JM, Clarisse B, Licaj I, Habrand JL, Carrie C, Joly F. Meyer E, et al. Among authors: hennequin c. Eur J Cancer. 2018 Jul;98:38-47. doi: 10.1016/j.ejca.2018.04.008. Epub 2018 Jun 1. Eur J Cancer. 2018. PMID: 29864737
Highly hypofractionated schedules for localized prostate cancer: Recommendations of the GETUG radiation oncology group.
Lapierre A, Hennequin C, Beneux A, Belhomme S, Benziane Ouaritini N, Biston MC, Crehange G, de Crevoisier R, Dumas JL, Fawzi M, Lisbona A, Pasquier D, Pelissier S, Graff-Cailleaud P, Pommier P, Sargos P, Simon JM, Supiot S, Tantot F, Chapet O. Lapierre A, et al. Among authors: hennequin c. Crit Rev Oncol Hematol. 2022 May;173:103661. doi: 10.1016/j.critrevonc.2022.103661. Epub 2022 Mar 25. Crit Rev Oncol Hematol. 2022. PMID: 35341986 Review.
Definition of lymph node areas for radiotherapy of prostate cancer: A critical literature review by the French Genito-Urinary Group and the French Association of Urology (GETUG-AFU).
Sargos P, Guerif S, Latorzeff I, Hennequin C, Pommier P, Lagrange JL, Créhange G, Chapet O, de Crevoisier R, Azria D, Supiot S, Habibian M, Soulié M, Richaud P. Sargos P, et al. Among authors: hennequin c. Cancer Treat Rev. 2015 Dec;41(10):814-20. doi: 10.1016/j.ctrv.2015.10.005. Epub 2015 Oct 23. Cancer Treat Rev. 2015. PMID: 26508669 Review.
External radiotherapy for prostatic cancers.
de Crevoisier R, Supiot S, Créhange G, Pommier P, Latorzeff I, Chapet O, Pasquier D, Blanchard P, Schick U, Marchesi V, Sargos P, Hennequin C. de Crevoisier R, et al. Among authors: hennequin c. Cancer Radiother. 2022 Feb-Apr;26(1-2):329-343. doi: 10.1016/j.canrad.2021.11.017. Epub 2021 Dec 23. Cancer Radiother. 2022. PMID: 34955419
Radiation-induced CD8 T-lymphocyte Apoptosis as a Predictor of Breast Fibrosis After Radiotherapy: Results of the Prospective Multicenter French Trial.
Azria D, Riou O, Castan F, Nguyen TD, Peignaux K, Lemanski C, Lagrange JL, Kirova Y, Lartigau E, Belkacemi Y, Bourgier C, Rivera S, Noël G, Clippe S, Mornex F, Hennequin C, Kramar A, Gourgou S, Pèlegrin A, Fenoglietto P, Ozsahin EM. Azria D, et al. Among authors: hennequin c. EBioMedicine. 2015 Oct 25;2(12):1965-73. doi: 10.1016/j.ebiom.2015.10.024. eCollection 2015 Dec. EBioMedicine. 2015. PMID: 26844275 Free PMC article. Clinical Trial.
Patterns of practice of androgen deprivation therapy combined to radiotherapy in favorable and unfavorable intermediate risk prostate cancer. Results of The PROACT Survey from the French GETUG Radiation Oncology group.
Belkacemi Y, Latorzeff I, Hasbini A, Coraggio G, Pasquier D, Toledano A, Hennequin C, Bossi A, Chapet O, Crehange G, Guerif S, Duberge T, Allouache N, Clavere P, Gross E, Supiot S, Azria D, Bolla M, Sargos P. Belkacemi Y, et al. Among authors: hennequin c. Cancer Radiother. 2020 Dec;24(8):892-897. doi: 10.1016/j.canrad.2020.03.014. Epub 2020 Nov 2. Cancer Radiother. 2020. PMID: 33144063 Review.
Dose constraints for moderate hypofractionated radiotherapy for prostate cancer: The French genito-urinary group (GETUG) recommendations.
Langrand-Escure J, de Crevoisier R, Llagostera C, Créhange G, Delaroche G, Lafond C, Bonin C, Bideault F, Sargos P, Belhomme S, Pasquier D, Latorzeff I, Supiot S, Hennequin C. Langrand-Escure J, et al. Among authors: hennequin c. Cancer Radiother. 2018 Apr;22(2):193-198. doi: 10.1016/j.canrad.2017.11.004. Epub 2018 Apr 5. Cancer Radiother. 2018. PMID: 29628205
Radiotherapy of breast cancer.
Hennequin C, Belkacémi Y, Bourgier C, Cowen D, Cutuli B, Fourquet A, Hannoun-Lévi JM, Pasquier D, Racadot S, Rivera S. Hennequin C, et al. Cancer Radiother. 2022 Feb-Apr;26(1-2):221-230. doi: 10.1016/j.canrad.2021.11.013. Epub 2021 Dec 23. Cancer Radiother. 2022. PMID: 34955414
[Indications and outlooks of radiohormonal therapy of high-risk prostate cancers].
Latorzeff I, Sargos P, Créhange G, Belkacémi Y, Azria D, Hasbini A, Dubergé T, Toledano A, Graff-Cailleaud P, Chapet O, Hennequin C, de Crevoisier R, Supiot S, Pasquier D. Latorzeff I, et al. Among authors: hennequin c. Cancer Radiother. 2020 Apr;24(2):143-152. doi: 10.1016/j.canrad.2019.06.018. Epub 2020 Feb 11. Cancer Radiother. 2020. PMID: 32057646 Review. French.
Randomized clinical trial of post-operative radiotherapy versus concomitant carboplatin and radiotherapy for head and neck cancers with lymph node involvement.
Racadot S, Mercier M, Dussart S, Dessard-Diana B, Bensadoun RJ, Martin M, Malaurie E, Favrel V, Housset M, Durdux C, Journel C, Calais G, Huet J, Pillet G, Hennequin C, Haddad E, Diana C, Blaska-Jaulerry B, Henry-Amar M, Géhanno P, Baillet F, Mazeron JJ. Racadot S, et al. Among authors: hennequin c. Radiother Oncol. 2008 May;87(2):164-72. doi: 10.1016/j.radonc.2007.12.021. Epub 2008 Jan 25. Radiother Oncol. 2008. PMID: 18222010 Clinical Trial.
559 results